Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times

Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment

New Delhi, Emcure Pharmaceuticals Ltd on Monday said its co-marketed brand of the innovator semaglutide, Poviztra, will now be available for the treatment of fatty liver.

This followed the Central Drugs Standard Control Organisation's (CDSCO) approval of 'Wegovy' for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, the company said in a statement.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.